Multiple Myeloma in Relapse Clinical Trial
— KMM-KCdOfficial title:
A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
Status | Not yet recruiting |
Enrollment | 49 |
Est. completion date | June 30, 2027 |
Est. primary completion date | June 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Subjects aged 19 years or older 2. ECOG performance status 0 to 2 3. Diagnosed with multiple myeloma by IMWG criteria 4. Subjects previously treated with 1 or more lines of therapy 5. Subjects previously treated with lenalidomide-based combination or sigle drug therapy 6. Subjects with relapsed and/or refractory multiple myeloma 7. Subjects with measurable disease at the time of treatment initiation - serum M protein >=0.5 g/dL, or - 24h urine M protein >= 200mg/24h - serum free light chain difference >=10mg/dL and abnormal FLC ratio 8. Adequate organ function - absolute neutrophil count >= 1.0 x 109/L - platelelt count >= 50 x 109/L (plasmacytoma in the bone: >=30 x 109/L) - Hb >=8g/dL - serum creatinine < 3.0mg/dL or CCR >=15mL/min - serum AST and ALT <=3 x ULN - serum total bilirubin <= 3 x ULN 9. Subjects able to swallow oral drugs 10. Subjects who had experienced toxicities to previous therapies: resolved from previous toxicities or stabilized of the toxicity to grade 1 11. Subjects who had received allogenetic stem cell transplantation: no acitve graft-versus-host disease 12. Subjects without clinically relevant bleeding 13. Subjects who have informed consent to the study 14. Females of childbearing potential (FCBP) must be negative to pregnancy testing and give consent to practice contraception before and during the treatment Exclusion Criteria: 1. Subjects who were previously exposed to carfilzomib 1. Subjects who were previously exposed to cyclophosphamide 3. Subjects diagnosed with POEMS SD, Waldenstrom macroglobulinemia, Plasma cell leukemia 4. Subjects with concurrent heart conditions - Myocardial infarction within 6 months prior to treatment, New York Heart Association class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, - Uncontrolled arrythmias (CVDAE version4 grade 2 or more) or symptomatic EKG abnormalities - 12-lead EKG : baseline ATcF > 470msec - 2D Echocardiography or MUGA scan : systolic EF < 40% with clinically significant symptoms - Uncontrolled hypertension ( with medication: systolic BP >= 160 mmHg or diastolic BP >= 100 mmHg) 5. Chronc obstructive pulmonary disease (FEV1 < 60%), history of asthma within 2 years 6. Surgery under general anesthesia withing 2 weeks 7. Subjects diagnosed with malignancies within 5 years (except for cured skin cancer, cervical cancer, intraepithelial gastrointestinal tract cancer after curative procedures or surgery for more than 3 years) 8. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent 9. Pregnant or breatfeeding subjecs |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Dong-A University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Very good partial response | Reduction of serum M-protein > 90% | from the first date of KCd to the day 30 after KCd stop date | |
Secondary | Overall response | sCR+CR+VGPR+PR | from the first date of KCd to the day 30 after KCd stop date | |
Secondary | Progression-free survival | the time from the first date of KCd to the date of disease progression or death or censored date | from the first date of KCd until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months | |
Secondary | Overall survival | the time from the first date of KCd to the date of death or censored date | from the first date of KCd until the date of death from any cause, assessed up to 48 months | |
Secondary | Duration of response | the time from the first date of PR to the date of disease progression or death or censord date | from the first date of PR to the date of disease progression or death or censord date, which ever came first, assessed up to 48 months | |
Secondary | Time to response | the time from the first date of KCd to the first date of partial response | from the first date of KCd to the date of first date of equal or more than partial response, which ever came first, assessed up to 48 months | |
Secondary | Safety profile | Adverse events after KCd | from the first date of KCd to day 30 after KCd stop date |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01435720 -
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04094961 -
Ixazomib + Pomalidomide + Dexamethasone In MM
|
Phase 1/Phase 2 | |
Recruiting |
NCT06068400 -
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
|
N/A | |
Recruiting |
NCT03601624 -
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
|
Phase 2 | |
Recruiting |
NCT05020444 -
TriPRIL CAR T Cells in Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT03706547 -
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
|
Phase 1 | |
Active, not recruiting |
NCT02970747 -
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
|
||
Not yet recruiting |
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 | |
Completed |
NCT01965353 -
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT05581875 -
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
|
Phase 1/Phase 2 | |
Terminated |
NCT03687125 -
Tinostamustine Conditioning and Autologous Stem Cell
|
Phase 1/Phase 2 | |
Recruiting |
NCT06282978 -
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
|
Phase 2 | |
Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT03030261 -
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04925193 -
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
Completed |
NCT03136653 -
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
|
Phase 1/Phase 2 |